Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesThe use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
Respiratory Medicine, 06/30/09
Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.
Related Articles
Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09
Relevance Score: 87%
Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09
Relevance Score: 85%
Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09
Relevance Score: 84%
“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09
Relevance Score: 84%
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09
Relevance Score: 83%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Taking the stress out of managing gout
Canadian Family Physician, 12/17/09
Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression
Anesthesiology, 12/17/09
Today in Pulmonology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cryptogenic Hemoptysis in Chronic Obstructive Pulmonary Disease: Characteristics and Outcome
Respiration, 12/17/09
Modifiable Risk Factors for Asthma Morbidity in Bronx Versus Other Inner-City Children
Journal of Asthma, 12/17/09
Congenital central hypoventilation syndrome: Neurocognitive functioning in school age children
Pediatric Pulmonology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor